Astellas Pharma Gmbh

Fujisawa Pharmaceutical Company, Ltd.

Kazuhiko Ohne

Kenichiro Imamura

Makoto Inoue

Yoshito Abe

Yuki Sawada

Kozo Sawada

Tsuyoshi Mizutani

Mitsuaki Okumura

Hiroshi Shibata

Kentaro Sato

Yuji Koga

Tsubasa Watanabe

Ichiro Shima

Takeshi Hanazawa

Yoshimasa Imamura

Eisuke Nozawa

Teruo Kyoto Oku

Masakazu Kobayashi

Susumu Yamaki

Masahiro Neya

Takehiko Ohkawa

Hitoshi Yamazaki

Akio Kuroda

Ippei Sato

Kyoichi Maeno

Shunichiro Hachiya

Naoki Ishibashi

Jiro Fujiyasu

Takeshi Hondo

Tomoyoshi Imaizumi

Kouichi Tamura

Keisuke Matsuura

Toshio Kurosaki

Ryo Mizoguchi

Satoshi Sasamura

Maiko Iida

Hiroki Ishioka

Tomohki Satou

Noriko Mukai

Keizo Sogabe

Atsushi Nomoto

Naomi Hosogai

Yoshimitsu Nakajima

Akira Nagashima

An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.

Imidazopyridine compounds

[Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.

[Problem] Provided is a compound which is useful as an agent for preventing and/or treating renal diseases. [Means for Solution] The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.

Guanidinobenzoic acid compound

The invention relates to compound of the formula (I) or its salt, in which R, R, Rand Rare as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-&#x3b1; mediated diseases. 

Pyrazolopyridine derivatives

The invention relates to compound of the formula (I) or its salt, in which R, R, Rand Rare as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-&#x3b1; mediated diseases 

Pyrrolopyridazine derivatives

A compound of formula (I) in which Ris halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, Ris amidated carboxy, Ris hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &#x3b1; (TNF &#x3b1;)

Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors

Substituted dipeptides having nos inhibiting activity

This invention relates to new aminopiperazine derivatives having the potentiation of the cholinergic activity, etc., and represented by general formula &lsqb;I&rsqb;.

Aminopiperazine derivatives

Indole derivatives as cGMP-PDE inhibitors

Growing community of inventors

Osaka, Japan

Kazuhiko Ohne